United States: CMS Releases Broad-Ranging Medicare Advantage And Part D Proposed Rule

Summary

CMS released a broad-ranging proposed rule for the Medicare Advantage and Part D Programs on Thursday, November 16, 2017. The proposed rule addresses a broad and diverse range of MA and Part D regulatory requirements, affecting not only Medicare Advantage Organizations and Part D Sponsors, but also health care providers, pharmacies, pharmaceutical manufacturers and others.

In Depth

The Centers for Medicare & Medicaid Services (CMS) released a broad-ranging proposed rule on Thursday, November 16, 2017 (the Proposed Rule) addressing key topics including Star Ratings, Medical Loss Ratios, Medicare marketing guidelines, Any Willing Pharmacy provisions, pharmacy rebates and a range of other topics. The Proposed Rule revisits past program decisions, implements certain provisions of the recently-enacted Comprehensive Addiction and Recovery Act of 2016 and the 21st Century Cures Act, and seeks to reduce regulatory burdens. CMS projects that the Proposed Rule will result in savings of approximately $195 million in the Medicare Advantage (MA) and Part D Programs over five years, at least some of which CMS anticipates would be passed on to Medicare beneficiaries in the form of lower premiums or additional benefits.

If finalized, the provisions of the Proposed Rule would impact a broad and diverse range of MA and Part D regulatory requirements, and would affect not only MAOs, but also health care providers, pharmacies, pharmaceutical manufacturers and others. Comments are due January 16, 2018. This article discusses a few of the key proposed changes and summarizes other substantive proposals.

Quality Star Ratings Changes

CMS proposes a variety of potentially significant changes to the Quality Star Ratings program, pursuant to which plans rated at 3.5 stars or above receive higher CMS payments to apply towards supplemental benefits or reduced member premiums. The changes include codifying a policy to downgrade ratings where data is biased or unreliable, changes to how ratings are assigned for consolidating contracts, and consideration of a variety of other issues.

Data Integrity. In the Proposed Rule, CMS proposes to codify its existing data integrity policy of reducing certain measure ratings to one star when the data used for that measure is inaccurate, incomplete or biased. CMS will apply this policy based on a contract's failure to score at least 95 percent on a data validation audit. CMS also proposes to impose scaled reductions, rather than an immediate reduction to one star, for data integrity concerns relating to Part C and D appeal measures, e.g., when CMS determines that a plan sponsor has not forwarded all untimely appeals cases to the Independent Review Entity. The new proposal for scaled reductions in Part C and D appeals ratings may reflect CMS's effort to provide a system to address findings from the industry-wide appeals timeliness monitoring effort it began in early 2017.

Consolidated Contracts. CMS also proposes a significant change to how it applies star ratings when two contracts are consolidated. Rather than applying the star rating of the surviving contract when two contracts consolidate, as is currently the case, CMS proposes to apply an enrollment-weighted average of the surviving and consumed contracts.

Other Star Rating Issues. Finally, CMS requests comments on a variety of additional topics related to star ratings, including issues that have been addressed in prior years but that CMS is apparently rethinking. These include issues such as whether ratings should be measured at the plan level rather than the contract level, how cut points for the various measures should be calculated and whether CMS should include a survey measure that captures physician experience with the plans, in addition to existing beneficiary surveys.

Codification of Star Ratings. For the first time, CMS proposes to issue regulations implementing the Quality Star Ratings program, which previously has been almost entirely governed through subregulatory guidance. As part of this proposal, CMS indicates that new quality measures will also be issued through formal notice and comment rulemaking in the future, although CMS would continue to use subregulatory guidance to modify existing measures.

Part D Any Willing Pharmacy (AWP) Requirements

The Proposed Rule attempts to strengthen the Part D AWP requirements, which are based in statute and implemented through existing regulations. While CMS has proposed some regulatory changes governing the provision of standard pharmacy contract terms to requesting pharmacies and defining certain types of pharmacies, the "clarifications" of existing regulations discussed in the preamble to the Proposed Rule may be just as significant as the proposed changes to the regulations.

Timeframe for Provision of Standard Terms and Conditions. CMS has proposed new regulations requiring Part D plan sponsors to provide pharmacies with standard terms and conditions within two business days of receiving a request for such materials. While this proposal mirrors subregulatory guidance issued in 2015, which stated that plans "should" provide these materials within two business days, the codification in regulation would make this a mandatory requirement. This proposal provides Part D plan sponsors with the opportunity to provide feedback to CMS on this approach, perhaps informed by efforts to comply with the earlier subregulatory guidance.

Definitions for Retail and Mail Order Pharmacy. CMS has also proposed a revised definition of "retail pharmacy" and a new definition for the previously undefined term "mail order pharmacy." CMS refers specifically to the use of the term "mail order pharmacy" in the 42 CFR § 423.120 convenient access standards and requirements regarding a level playing field between retail and mail order pharmacies, but acknowledges broadly that the term is used in other regulations and subregulatory guidance. The proposed definition for mail order pharmacy is "a licensed pharmacy that dispenses and delivers extended days' supplies of covered Part D drugs via common carrier at mail-order cost sharing." As both retail and mail order pharmacies must be permitted to provide extended days' supplies and a growing number of retail pharmacies engage in limited delivery of drugs by common carrier, the key criteria in this definition that appears to distinguish mail order pharmacies from retail pharmacies is the reference to mail-order cost sharing. As the imposition of retail versus mail order cost sharing at a particular pharmacy could in turn be determined by a Part D plan sponsor's or pharmacy benefit manager's definition of mail order pharmacy, there may be questions about how the proposed regulatory definition—if not further refined following industry comment—would be interpreted in practice and impact other Part D requirements.

Clarifications Regarding Reasonable and Necessary Contract Terms. In contrast to the flexibility- and competition-enhancing proposals set forth in other sections of the Proposed Rule, the discussion regarding AWP requirements signals CMS's renewed interest in more closely regulating Part D pharmacy contracting. CMS previously attempted to strengthen these rules in a 2014 proposed rule, but ultimately did not finalize these more controversial proposals. Existing statutory and regulatory requirements set forth at Section 1860D-4(b)(1)(A) of the Social Security Act and 42 CFR § 423.505(b)(18) require Part D plan sponsors "to have a standard contract with reasonable and relevant terms and conditions of participation whereby any willing pharmacy may access the standard contract and participate as a network pharmacy." The preamble to the Proposed Rule purports to "clarify" the meaning of "reasonable and relevant terms and conditions" but does not propose to codify any of these clarifications in new regulations.

CMS's clarifications may suggest that Part D plans should not impose requirements, e.g., plan-specific accreditation or credentialing criteria, that could potentially prevent a pharmacy from participating in the plan's network, stating that "where there are barriers to a pharmacy's ability to participate in the network at all, it raises the question of whether the standard (that is, entry-level) terms and conditions are reasonable and relevant." CMS also states that it is "especially concerned about anecdotal reports that allege such standard terms and conditions for network participation are waived, for example, when a Part D plan sponsor needs a particular pharmacy in its network in order to meet convenient access requirements," and suggests that this results in the criteria no longer being considered "standard." In contrast, existing CMS guidance recognizes that deviation from standard terms may be required for network access reasons – "[i]t is unlikely that a Part D sponsor could establish a network using a uniform set of terms and conditions throughout a service area because it will likely need to modify contracting terms and conditions to ensure access to certain pharmacies – for example, rural and long-term care pharmacies." (Prescription Drug Benefit Manual, Ch. 5, § 50.8.1)

The proposed clarifications to the AWP rules take a different approach than the rules proposed in 2014, but reflect CMS's continued desire to strengthen Part D AWP requirements. As in 2014, the agency's interpretation of existing rules may raise questions about the scope of CMS's authority to regulate Part D plan sponsor relationships with pharmacies. Specifically, the "non-interference provision," set forth at Section 1860D-11(i) of the Social Security Act, prohibits CMS from "interfer[ing] with the negotiations between drug manufacturers and pharmacies and PDP sponsors." The Federal Trade Commission and other organizations have cautioned CMS about the anti-competitive and pricing impacts of strengthening existing AWP requirements in the Part D program; this Proposed Rule may elicit similar reactions.

Medical Loss Ratio (MLR) Changes

CMS proposes changes to the Medicare MLR calculation to explicitly allow numerator treatment for fraud reduction expenses and reduce reporting obligations. Specifically, CMS proposes to include fraud prevention, detection and recovery activities in quality improvement activities, which would receive MLR numerator treatment. Current regulations exclude such expenses from the numerator, but the amount of claim payments recovered through fraud reduction efforts, up to the amount of a plan's fraud reduction expenses, are included as an adjustment to the incurred claims. The Proposed Rule would simply allow fraud prevention, detection and recovery activities to be included in quality improvement activities without limitation, but would eliminate the provision allowing recovered claims payments to remain in "incurred claims." The change would apply only for MA and Part D, and not to commercial or Medicaid MLR requirements. CMS also proposes to allow Part D Medication Therapy Management program expenses to count towards Quality Improvement Activities if such programs meet applicable regulatory standards.

CMS proposes to significantly limit MLR reporting requirements, reducing reporting to just the following four fields: organization name, contract number, adjusted MLR and remittance amount. However, CMS notes that it would still retain its authority to conduct audits of MLR data, so plans might need to prepare and maintain more detailed data even if that detail is not initially required to be submitted to CMS. CMS's proposed revision to the reporting requirements does not change the obligation for plan sponsors (and their subcontractors, as applicable) to retain MLR-related documentation for ten years pursuant to 42 CFR §§ 422.2480(c)(1) and 423.2480(c)(1).

Other Proposals

The Proposed Rule also includes a number of additional proposed regulatory changes, including:

  • Flexibility in Benefits / Increasing Choice and Competition

    • Revise current interpretation of Sections 1852(d) and 1854(c) of the Social Security Act and 42 CFR § 422.100(d) (the so-called uniform benefit requirements) to permit MA organizations to modify plan benefits (e.g., cost-sharing, deductibles, and supplemental benefits) for members based on health status or disease state. CMS states that it would issue further clarification regarding this new flexibility through subregulatory guidance, without issuing any regulatory changes. Under the proposed approach, cost-sharing reductions and supplemental benefits offered to individuals based on health status would need to be medically related to the condition(s) at issue. Section 1557 of the Affordable Care Act and other civil rights laws may constrain the scope of this authority.
    • Permit variation in supplemental benefits by plan segment (county-level portions of a plan's overall service area), in addition to variation in premiums and cost-sharing amounts by plan segment, as is currently permitted.
    • Repeal MA and some Part D meaningful difference rules.
  • Marketing and Enrollment

    • Narrow the scope of marketing materials subject to CMS review and approval.
    • Permit electronic delivery of the annual Evidence of Coverage and certain other beneficiary communications.
    • Codify a new open enrollment period for MA plan members, as established in the 21st Century Cures Act, which permits individuals enrolled in an MA plan to make a one-time election to switch to another MA plan or Original Medicare between January 1 and March 31 of each year.
    • Create additional authority for CMS to permit seamless and passive enrollment of dual eligible beneficiaries into Dual Eligible Special Needs Plans under certain circumstances.
    • Limit special enrollment periods for Low-Income Subsidy members.
  • Part D Proposals

    • Provide new authority for Part D plan sponsors to address opioid overutilization, consistent with the requirements set forth in the Comprehensive Addiction and Recovery Act of 2016.
    • Permit Part D plan sponsors to make generic substitutions on a plan formulary without advance approval by CMS.
    • Treat biosimilars like generic drugs for purposes of certain cost-sharing requirements.
    • Impose new rules for tiering exceptions.
    • Lengthen the timeframe for Part D standard redetermination requests for payment from 7 calendar days to 14 calendar days.
    • Adopt updated e-prescribing standards.
    • Solicit comments on how CMS might most effectively require Part D sponsors to pass through a share of manufacturer rebates at the point of sale and the potential impact of this type of requirement (e.g., a rule that Part D plan sponsors must include a specified minimum percentage of rebates in the negotiated price). CMS has not proposed any specific regulatory provisions on this topic in the Proposed Rule, but rather is seeking information for future rulemakings.
  • Compliance-Related Provisions

    • Replace requirements governing provider and prescriber enrollment in Medicare with a prohibition on MA and Part D plan sponsors paying claims for providers on the "preclusion list."
    • Reduce first-tier, downstream, and related entity compliance program training requirements.
  • Other Proposals

    • Remove Quality Improvement Program requirements for MA plans.
    • Revise long-standing Physician Incentive Plan rules, requesting comment on whether the definitions of "substantial financial risk" and "risk threshold" set forth in the current regulation should be revised in light of changes in the current environment.
    • Remove limitations on the actions plans can take when a previously licensed agent or broker becomes unlicensed.
    • Provide new authority for CMS to establish Maximum Out-of-Pocket limits using alternative methodologies (e.g., based on Original Medicare).

CMS Releases Broad-Ranging Medicare Advantage and Part D Proposed Rule

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions